10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2012 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2012 | Dec 31, 2011 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 1,656 | 5,776 |
| Marketable securities | 1,173 | 2,957 |
| Receivables | 3,083 | 3,743 |
| Inventories | 1,657 | 1,384 |
| Deferred income taxes | 1,597 | 1,200 |
| Prepaid expenses and other | 355 | 258 |
| Total Current Assets | 9,521 | 15,318 |
| Property, plant and equipment | 5,333 | 4,521 |
| Goodwill | 7,635 | 5,586 |
| Other intangible assets | 8,778 | 3,124 |
| Deferred income taxes | 203 | 688 |
| Marketable securities | 3,523 | 2,909 |
| Other assets | 904 | 824 |
| Total Assets | 35,897 | 32,970 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short term borrowings and current portion of long-term debt | 115 | |
| Short-term borrowings and current portion of long-term debt | 826 | |
| Accounts payable | 2,202 | 2,603 |
| Accrued expenses | 2,573 | 2,791 |
| Deferred income | 825 | 337 |
| Accrued rebates and returns | 1,054 | 1,170 |
| U.S. and foreign income taxes payable | 193 | 167 |
| Dividends payable | 606 | 597 |
| Total Current Liabilities | 8,279 | 7,780 |
| Pension, postretirement, and postemployment liabilities | 1,882 | 2,017 |
| Deferred income | 4,024 | 866 |
| U.S. and foreign income taxes payable | 648 | 573 |
| Deferred income taxes | 383 | 107 |
| Other liabilities | 475 | 384 |
| Long-term debt | 6,568 | 5,376 |
| Total Liabilities | 22,259 | 17,103 |
| Commitments and contingencies (Note 21) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,117 in 2012 and 5,268 in 2011, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2012 and 2011 | 221 | 220 |
| Capital in excess of par value of stock | 2,694 | 3,114 |
| Accumulated other comprehensive loss | (3,202) | (3,045) |
| Retained earnings | 32,733 | 33,069 |
| Less cost of treasury stock - 570 million common shares in 2012 and 515 million in 2011 | (18,823) | (17,402) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 13,623 | 15,956 |
| Noncontrolling interest | 15 | (89) |
| Total Equity | 13,638 | 15,867 |
| Total Liabilities and Equity | 35,897 | 32,970 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |